The prevalence of diabetes is increasing worldwide, highlighting the need for the development of innovative therapeutic approaches for the prevention and cure of diabetes. Mounting evidence points to the involvement of multiple immune dysfunctions both in type 1 diabetes (T1D, caused by autoimmunity) and in type 2 diabetes (T2D, caused by insulin resistance). Dr.Yong Zhao has brought about an innovative technology—Stem Cell Educator therapy. Our revolutionizing technology is taking steps to the ultimate cure of diabetes as it also has laid foundation to the cure of other autoimmune diseases.
TianheStem CellBiotechnologies Inc. has licensed a whole series of patented technologies from the isolation of human cord blood-derived multipotent stem cells (CB-SCs) to clinical applications. It has a major division in China, JinanTianheStem CellBiotechnology Co., Ltd., located inJinanHigh-techBioindustryParkDistrict. Currently, Tianheis focusing on the application of Stem Cell Educator therapy in diabetes. Notably, our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to regeneration of islet beta cells and improvement of metabolic control in long-standing diabetic subjects. This principle may also be beneficial in the treatment of other autoimmune-related diseases.
July 9 2013 -Dr.Zhao and his team published
the Phase I/II clinical trial data in type 2 diabetes, at the peer review
clinical journal BMC Medicine. The
clinical data demonstrate the safety and efficacy of Stem Cell Educator therapy
for the treatment of type 2 diabetes.Stem Cell Educator therapy opens up new
avenues to find a cure for type 1 diabetes andtype 2 diabetes.